LUCD Lucid Diagnostics
- 0.879
- -0.022-2.48%
- 0.856
- -0.023-2.61%
Lucid Diagnostics News
Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses
Lucid Diagnostics Analyst Ratings
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position
Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives
Buy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare Reimbursement
Lucid Diagnostics Analyst Ratings
BTIG Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)
BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
Needham Reiterates Buy on Lucid Diagnostics Following Investor Day
Analysts Offer Insights on Healthcare Companies: Atreca (BCEL), Lucid Diagnostics (LUCD) and Vertex Pharmaceuticals (VRTX)
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.5
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $4 Price Target
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics Analyst Ratings
Needham Adjusts Price Target on Lucid Diagnostics to $2.80 From $2.60, Maintains Buy Rating
Analysis
Price Target
No Data
